Why the study?
Does the HAS-BLED score accurately assess the 1-year risk of major bleeding in patients with atrial fibrillation?
Does the HAS-BLED score accurately assess the 1-year risk of major bleeding in patients with atrial fibrillation?
The novel HAS-BLED score provides a practical tool to assess individual 1-year major bleeding risk in real-world patients with atrial fibrillation, supporting clinical decision-making for antithrombotic therapy.
May aid AF bleeding risk assessment; leaves open need for prospective validation before practice change.
This simple, novel bleeding risk score (HAS-BLED) provides a practical tool to assess the individual bleeding risk of real-world patients with AF, potentially supporting clinical decision making regarding antithrombotic therapy in patients with AF.
No takes yet. Share an insight, caveat, or question.
Pisters et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: